The Advertising Standards Authority has banned a billboard advertisement for a £49 face serum after ruling that claims it could make users appear as much as five years younger were misleading and unsubstantiated. The poster for Eucerin Hyaluron-Filler Epigenetic Serum, which appeared at Balham tube station in London, stated the product was “clinically proven” founded on a research involving 160 people. However, the watchdog found significant flaws in the research methodology, including the absence of a control group and dependence on subjective self-assessment from participants. The grievance was lodged in November 2025, prompting the ASA investigation that ultimately deemed the advert deceptive and banned it from appearing in its current form.
The Prohibited Campaign and Its Questionable Claims
The Eucerin advertisement relied heavily on a four-week study featuring 160 participants who were simply asked to provide self-reported accounts of how much younger they felt they appeared after applying the serum. This methodology prompted immediate concerns for the ASA, which identified multiple significant weaknesses in the study design. Particularly important, the study did not include a comparison group—a essential component in scientific research that would have allowed researchers to compare results against a reference point. The lack of such controls meant there was no means to determine whether any apparent benefits were genuinely attributable to the serum or simply the result of placebo effect, inherent skin differences, or additional outside influences.
Beiersdorf, the organisation behind Eucerin, attempted to defend the “up to five years younger” claim by contending it represented a genuine maximum result rather than a standard result. However, the concerns raised by the ASA extended further than the main investigation. The watchdog highlighted that the serum had been evaluated in a different climate to the United Kingdom, prompting concerns about whether findings would apply to British consumers. Additionally, three additional pieces of evidence provided by Beiersdorf consisted entirely of unpublished studies, whilst a fourth item—a study that had been peer-reviewed on the active ingredient—did not even evaluate the serum itself, further eroding the support for the strong anti-ageing claims.
- Study lacked control group to confirm genuine product efficacy
- Self-reporting by participants created personal bias into results
- Testing conducted in different climate than UK market
- Supporting evidence predominantly unpublished and methodologically flawed
Compliance Issues and Problematic Approach
Why the Study Did Not Meet Standards
The ASA’s examination uncovered significant weaknesses in how Beiersdorf conducted and presented its research. The lack of clear recruitment information meant the watchdog could not verify whether participants were genuinely representative of the wider consumer population or if sampling bias had biased outcomes towards positive results. Without knowing how volunteers were recruited, whether they had previous exposure with skincare products, or if they maintained brand preference for the brand, the trustworthiness of their feedback became highly questionable. These methodological gaps are the very type that regulatory bodies examine closely when reviewing statements that could affect consumer choices.
Self-reporting by study participants introduced a substantial layer of subjective bias into the findings. Asking individuals to gauge how many years younger they appeared is inherently unreliable, as perceptions of ageing are highly individual and influenced by psychological factors, environmental lighting, and individual expectations. The ASA appropriately challenged whether participants’ responses reflected genuine physical changes or merely their hopes and beliefs about the product’s efficacy. This distinction holds significant weight when a company seeks to market a £49 serum as “clinically proven”—a phrase implying rigorous, objective scientific validation rather than subjective personal impressions.
- No control group meant unable to determine product’s true effects
- Recruitment process undisclosed, introducing selection bias concerns
- Personal self-reporting cannot constitute scientific evidence of efficacy
- Varying environmental conditions compromised applicability to UK consumers
- Supporting evidence largely unpublished, preventing third-party scrutiny
Common Challenge with Beauty Promotion
The Eucerin serum ban is simply the most recent example of misleading claims that has plagued the cosmetics advertising industry for years. Beauty companies have repeatedly pushed the limits of permissible marketing language, utilising aspirational language and scientific-sounding terminology to convince consumers that products deliver dramatic outcomes. Lianne Sykes, an marketing specialist in aesthetics who consults with firms on ethical advertising practices, stresses that this problem is widespread rather than being isolated. Companies often place emphasis on persuasive marketing stories over thorough evidence, relying on the presumption that consumers will not examine claims too closely or that regulatory enforcement will be slow.
The cosmetics sector gains from inherent consumer desire for visible improvements in appearance, creating fertile ground for inflated statements. When brands use phrases like “clinically proven” without meeting the stringent standards that such language demands, they undermine the trust people invest in scientific terminology. The ASA’s findings suggest that Beiersdorf’s approach—offering unpublished research, running studies in inappropriate conditions, and relying on subjective self-assessment—exemplifies a worrying but not uncommon strategy. Without sustained oversight and improved disclosure from suppliers, consumers stay susceptible to marketing claims that prioritise sales over honesty.
What People Should Question
Rather than accepting beauty product claims uncritically, consumers should establish a more critical approach to scrutinising cosmetic advertising. Sykes advises raising important questions prior to buying, particularly when companies put forward assertions about tangible results. Understanding the testing methods used, who takes part in studies, and what data points are measured can demonstrate whether claims are based on solid evidence or promotional claims. Consumers must recognise that healthy skin generally stems from steady practices and personal genetics rather than putting faith in a one wonder product, irrespective of its price point or branding.
- How is skin condition systematically assessed and tracked over time?
- Were trials conducted on diverse age groups and skin conditions?
- Is the evidence published and objectively verifiable by scientists?
- Does the test conditions match real-world conditions where consumers live?
Beiersdorf’s Reaction and Future Implications
Beiersdorf, the multinational enterprise based in Germany that owns the Eucerin brand, has maintained that its products are underpinned by legitimate scientific research conducted in accordance with industry standards. The company justified its decision to present the claim as “up to” five years younger, contending this phrasing correctly captured the true maximum outcome detected rather than a typical outcome. However, the ASA’s thorough examination of the methodology—including the absence of a control group, absence of clarity about how participants were selected, and dependence on subjective self-assessment—suggests that industry standards alone might not be adequate to protect consumers from misleading assertions.
The prohibition signals a wider movement in regulatory oversight against cosmetics advertising, though uncertainty persists about whether individual instances translate into widespread reform. Beiersdorf confirmed that the billboard advertisement is no longer live in the UK, but the ruling raises important questions about how widely similar claims exist throughout other products and promotional platforms. If enforcement continues at this pace, companies could experience increasing demands to commit resources to truly comprehensive clinical evidence rather than depending on the ambiguity of unverified research. For consumers, this case underscores the necessity of requiring openness and scrutinising even well-established brands.